Manufacturing Validation of Biologically Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell Therapy

On the basis of promising preclinical data demonstrating the eradication of systemic B-cell malignancies by CD19-targeted T lymphocytes in vivo in severe combined immunodeficient-beige mouse models, we are launching phase I clinical trials in patients with chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia. We present here the validation of the bioprocess which we developed for the production and expansion of clinical grade autologous T cells derived from patients with CLL. We demonstrate that T cells genetically modified with a replication-defective gammaretroviral vector derived from the Moloney murine leukemia virus encoding a chimeric antigen receptor (CAR) targeted to CD19 (1928z) can be expanded with Dynabeads CD3/CD28. This bioprocess allows us to generate clinical doses of 1928z+ T cells in approximately 2 to 3 weeks in a large-scale semiclosed culture system using the Wave Bioreactor. These 1928z+ T cells remain biologically functional not only in vitro but also in severe combined immunodeficient-beige mice bearing disseminated tumors. The validation requirements in terms of T-cell expansion, T-cell transduction with the 1928z CAR, biologic activity, quality control testing, and release criteria were met for all 4 validation runs using apheresis products from patients with CLL. Additionally, after expansion of the T cells, the diversity of the skewed Vβ T-cell receptor repertoire was significantly restored. This validated process will be used in phase I clinical trials in patients with chemorefractory CLL and in patients with relapsed acute lymphoblastic leukemia. It can also be adapted for other clinical trials involving the expansion and transduction of patient or donor T cells using any CAR or T-cell receptor.

[1]  A. Grañena,et al.  Relapse after allogeneic bone marrow transplantation for acute leukaemia: a survey by the E.B.M.T. of 117 cases , 1988, British journal of haematology.

[2]  P. Marrack,et al.  Interaction of Staphylococcus aureus toxin "superantigens" with human T cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[3]  A. Gratwohl,et al.  Second transplants for leukaemic relapse after bone marrow transplantation: high early mortality but favourable effect of chronic GVHD on continued remission. A REPORT BY THE EBMT LEUKAEMIA WORKING PARTY , 1991, British journal of haematology.

[4]  S. Roman-Roman,et al.  An experimentally validated panel of subfamily‐specific oligonucleotide primers (Vα1‐w29/Vβ1‐w24) for the study of human T cell receptor variable V gene segment usage by polymerase chain reaction , 1992, European journal of immunology.

[5]  R. Mulligan,et al.  Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[6]  J L Riley,et al.  Large-scale production of CD4+ T cells from HIV-1-infected donors after CD3/CD28 costimulation. , 1998, Journal of hematotherapy.

[7]  Cahn,et al.  Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Société Française de Greffe de Moelle (SFGM) , 2000, British journal of haematology.

[8]  Guidance for Industry.  Supplemental guidance on testing for replication-competent retrovirus in retroviral vector-based gene therapy products and during follow-up of patients in clinical trials using retroviral vectors. , 2001, Human gene therapy.

[9]  J. Thompson,et al.  Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[10]  D. Birx,et al.  Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection , 2002, Nature Medicine.

[11]  S. Chouaib,et al.  Differential STAT3, STAT5, and NF-kappaB activation in human hematopoietic progenitors by endogenous interleukin-15: implications in the expression of functional molecules. , 2003, Blood.

[12]  S. Larson,et al.  Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15 , 2003, Nature Medicine.

[13]  J. Byrd,et al.  Advances in the therapy of chronic lymphocytic leukemia. , 2003, Current opinion in hematology.

[14]  S. Grupp,et al.  Adoptive transfer of costimulated T cells induces lymphocytosis in patients with relapsed/refractory non-Hodgkin lymphoma following CD34+-selected hematopoietic cell transplantation. , 2003, Blood.

[15]  S. Craig,et al.  GMP production and testing of Xcellerated T Cells for the treatment of patients with CLL. , 2004, Cytotherapy.

[16]  B. Levine,et al.  Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cells , 2004, Bone Marrow Transplantation.

[17]  S. Rosenberg,et al.  Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[18]  T. Kipps,et al.  A Phase I/II Trial of Xcellerated T Cells™ in Patients with Chronic Lymphocytic Leukemia. , 2004 .

[19]  J. Buckner,et al.  Optimization of Human T-Cell Expansion Ex Vivo Using Magnetic Beads Conjugated with Anti-CD3 and Anti-CD28 Antibodies , 2004, Journal of immunotherapy.

[20]  Richard Carroll,et al.  Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[21]  Antonio Lanzavecchia,et al.  Central memory and effector memory T cell subsets: function, generation, and maintenance. , 2004, Annual review of immunology.

[22]  S. Rosenberg,et al.  Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  W. Blackwelder,et al.  Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer , 2005, Nature Medicine.

[24]  E. Robinet,et al.  In Vitro Engagement of CD3 and CD28 Corrects T Cell Defects in Chronic Lymphocytic Leukemia1 , 2005, The Journal of Immunology.

[25]  C. Klebanoff,et al.  CD8+ T‐cell memory in tumor immunology and immunotherapy , 2006, Immunological reviews.

[26]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[27]  M. Sadelain,et al.  Production scale-up and validation of packaging cell clearance of clinical-grade retroviral vector stocks produced in Cell Factories , 2006, Gene Therapy.

[28]  Alexander Perl,et al.  A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. , 2006, Blood.

[29]  M. Sadelain,et al.  268. CD19-Targeted Normal and CLL Patient T Cells Expanded with Beads Can Eradicate Systemic Tumors In Vivo , 2006 .

[30]  S. Larson,et al.  Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts , 2007, Clinical Cancer Research.

[31]  M. Bonyhadi,et al.  Cell isolation and expansion using Dynabeads. , 2007, Advances in biochemical engineering/biotechnology.

[32]  M. Sadelain,et al.  T cell–encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection , 2007, Nature Medicine.

[33]  S. Forman,et al.  Manufacturing of Large Numbers of Patient-specific T Cells for Adoptive Immunotherapy: An Approach to Improving Product Safety, Composition, and Production Capacity , 2007, Journal of immunotherapy.

[34]  M. Sadelain,et al.  Multifactorial optimization of gammaretroviral gene transfer into human T lymphocytes for clinical application. , 2007, Human gene therapy.

[35]  Jinjuan Wang,et al.  Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. , 2008, Blood.

[36]  Mike Gough,et al.  Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. , 2008, The Journal of clinical investigation.

[37]  Jianhong Cao,et al.  Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. , 2008, The New England journal of medicine.

[38]  R. Lindblad,et al.  A multicenter comparison study between the Endosafe PTS rapid-release testing system and traditional methods for detecting endotoxin in cell-therapy products. , 2008, Cytotherapy.